Developing the Vascular Quality of Life Questionnaire: A new disease-specific quality of life measure for use in lower limb ischemia

Morgan, M.; Crayford, Tim; Murrin, Ben; Fraser, S. C. A.

doi:10.1067/mva.2001.112326

Cited by 225 publications

(202 citation statements)

References 23 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…32,33 Table 2 lists characteristics of some of the currently available and most commonly used CVD-specific patient health status surveys for CAD, atrial fibrillation, heart failure, and PAD.…”

Section: Patient Health Status Surveysmentioning

confidence: 99%

Cardiovascular Health: The Importance of Measuring Patient-Reported Health Status

Rumsfeld¹,

Alexander²,

Goff³

et al. 2013

Circulation

467

406

View full text Add to dashboard Cite

Section: Patient Health Status Surveysmentioning

confidence: 99%

Cardiovascular Health: The Importance of Measuring Patient-Reported Health Status

Rumsfeld¹,

Alexander²,

Goff³

et al. 2013

Circulation

467

406

View full text Add to dashboard Cite

“…The Vascular Quality of Life Questionnaire (VASCUQOL) 5 contains 25 items categorized into the domains of social and emotional well-being, pain, symptoms and activities. This questionnaire was originally developed for patients who had symptomatic PAD and had a Fontaine classification of II-IV (claudication, ischemic rest pain or tissue loss).…”

Section: Introductionmentioning

confidence: 99%

The PADQOL: Development and validation of a PAD-specific quality of life questionnaire

et al. 2012

View full text Add to dashboard Cite

Understanding the impact of peripheral artery disease (PAD) requires broad evaluation of how functional limitations of PAD affect patients' perceptions of health-related quality of life (HRQL). The objective of this study was to describe the development, testing, and psychometric properties of the PAD Quality of Life Questionnaire (PADQOL). The PADQOL was developed in three steps: (1) interviews of symptomatic PAD patients provided content of the initial questionnaire; (2) co-administration with the SF-36 (a 36-item short-form health survey), Walking Impairment Questionnaire, and Profile of Mood States examined construct validity; and (3) a three-phased factor analysis identified factors and shortened the questionnaire. Data analyses from 297 symptomatic PAD patients resulted in a 38-item questionnaire of five factors: Social relationships and interactions, Self-concept and feelings, Symptoms and limitations in physical functioning, Fear and uncertainty, and Positive adaptation (α = 0.92-0.73) and items related to sexual function, intimate relationships and employment. Between-instrument correlations established construct validity. In conclusion, PADQOL is a validated measure to assess the disease-specific physical, psychosocial and emotional effects of PAD for research and practice.

show abstract

“…There are also data available for the Walking Impairment Questionnaire (WIQ 85 ) for both cilostazol and pentoxifylline, although this measure aims to assess walking impairment and not quality of life. Other outcome measures used include the claudication outcome measure (COM -a measure developed by the funders but which had not undergone validation, 61 and does not appear to have been published), vascular quality of life (VascuQoL), 86 an independent measure that has been validated, and the Claudication Scale (CLAU-S), another independent, extensively validated tool. 87 Tables 51-54 summarise the evidence around HRQoL.…”

Section: 58mentioning

confidence: 99%

A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.

Squires

Simpson²,

Meng³

et al. 2011

Health Technol Assess

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research a...

show abstract

Developing the Vascular Quality of Life Questionnaire: A new disease-specific quality of life measure for use in lower limb ischemia

Abstract: This disease-specific questionnaire is reliable, responsive, valid, and ready for use as an outcome measure in clinical trials. It is sensitive to the concerns of patients with lower limb ischemia, offering a simple method to measure the effect of interventions on their QOL.

Cited by 225 publications

References 23 publications

Cardiovascular Health: The Importance of Measuring Patient-Reported Health Status

Cardiovascular Health: The Importance of Measuring Patient-Reported Health Status

The PADQOL: Development and validation of a PAD-specific quality of life questionnaire

A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.

Contact Info

Product

Resources

About